1. Generics Bulletin
  2. >>Products

IGBA Makes Access Pact With WHO

Promotes The Use Of Generics And Biosimilars

 
• By Dave Wallace

The WHO has taken an “important first step” towards increased collaboration with the generics and biosimilars industries through an agreement with the IGBA to promote access to medicines, including working towards a reduced trial burden for biosimilars and speeding up registration for both generics and biosimilars.

Pills_World_Map
The global agreement will promote access to generics and biosimilars • Source: Shutterstock

A pact has been struck between the World Health Organization and the International Generic and Biosimilar Medicines Association that the WHO says “highlights the role of the pharmaceutical industry in helping WHO maintain tools that can facilitate registration of generic and biosimilar medicines.”

The memorandum of understanding – which the WHO described as “an important first step towards increased collaboration with the generic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Celltrion Reinforces Commitment To UK Biosimilars Market With New HQ

 
• By Dave Wallace

Celltrion has reinforced its commitment to the UK by opening a new central operations hub in Uxbridge, while acknowledging that “major questions over the attractiveness of the market” need to be addressed to encourage development and ensure a sustainable environment for UK biosimilars.

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

Tevogen Will House Generics Unit In Much-Expanded New Headquarters

 
• By Dean Rudge

Tevogen is looking to accelerate its growth with a major expansion of its headquarters in Warren, New Jersey, more than doubling its footprint to centralize research and development, regulatory, and corporate functions. The new facility will support the company’s evolving initiatives.